Content about Glycogen storage disease type II

April 7, 2011

Pfizer is partnering with San Diego biotech company Zacharon Pharmaceuticals to develop treatments for rare genetic disorders Zacharon said Thursday.

February 16, 2011

Sanofi-Aventis obtains Genzyme for $20.1 billion

French drug maker Sanofi-Aventis will acquire U.S. biotech giant Genzyme for $20.1 billion, under an agreement the two companies announced Wednesday.

January 20, 2011

Report: Genzyme CEO calls acquisition by Sanofi-Aventis a long process

Finalizing an acquisition of biotech company Genzyme by French drug maker Sanofi-Aventis “will take some time,” media reports quoted Genzyme’s chief executive as saying.

January 10, 2011

Sanofi, Genzyme get closer to deal

It appears that French drug maker Sanofi-Aventis’ efforts to acquire U.S. biotech company Genzyme are getting somewhere, according to company and media reports.

August 29, 2010

BioMarin's Pompe disease treatment gets orphan-drug designation

BioMarin Pharmaceutical on Monday announced its investigational treatment for a lysosomal storage disorder has received...

August 25, 2010

Sanofi unwilling to increase bid with Genzyme

Biotech drug maker Genzyme’s takeover by French drug maker Sanofi-Aventis may have run into trouble,...

August 19, 2010

BioMarin Pharmaceutical acquires ZyStor Therapeutics

BioMarin Pharmaceutical has acquired privately owned biotechnology company ZyStor Therapeutics for $22 million, BioMarin said....

May 24, 2010

FDA approves Pompe disease treatment

The Food and Drug Administration has approved a new treatment for a rare genetic disorder...